Intensity Therapeutics, Inc. (INTS) Stock

Healthcare · Biotechnology · Member of Other US Stocks

Intensity Therapeutics, Inc. (INTS) closed at USD 3.42 on 2026-10-14, a change of -45.7 % over the past year, with a market capitalization of USD 11.04M.

Intensity Therapeutics, Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Intensity Therapeutics, Inc. key figures

Previous close

USD 3.42 (2026-10-14)

1-year change

-45.7 %

Market cap

USD 11.04M

Enterprise value

USD 1.6M

P/E ratio (trailing)

-0.90

P/E ratio (forward)

-1.70

EPS (trailing)

-3.77

EPS (forward)

-1.99

PEG ratio

n/a

Price to book

1.08

Revenue growth

n/a

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

2.55

Employees

5

Analyst consensus (third-party)

none

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Intensity Therapeutics, Inc.

Intensity Therapeutics, Inc., a late-stage clinical biotechnology company, engages in the provision of treatment for the regional and systemic nature of cancer relapse and metastasis in the United States. Its lead product candidate includes INT230-6, which is in Phase 3 clinical studies for the treatment of soft tissue sarcoma; and neoadjuvant and metastatic triple negative breast cancer which is in Phase 2 clinical trials. The company was incorporated in 2012 and is headquartered in Shelton, Connecticut.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Intensity Therapeutics, Inc. and compare it with other stocks.